Back to Directory Shane Reynolds Email Phone Institution FHI 360 Role Clinical Trials Specialist Address FHI 360 359 Blackwell Street Suite 200 Durham, NC 27701 USA Request an Update Affiliated Studies IMPAACT 2024 : Phase I/II Dose Finding and Safety Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Infants, Children and Adolescents DAIDS Number 38747 Research Area Tuberculosis Study Status In Development Locality US & Non-US P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants DAIDS Number 11882 Research Area Treatment Study Status Closed to Follow Up Locality Non-US IMPAACT 2007: Phase I Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed Locality US & Non-US P1006: Effects of HAART on Immune Function DAIDS Number 10036 Research Area Other Study Status Concluded Locality United States IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age DAIDS Number 38530 Research Area Complications & Comorbidities Study Status Enrolling Locality United States Show All
IMPAACT 2024 : Phase I/II Dose Finding and Safety Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Infants, Children and Adolescents DAIDS Number 38747 Research Area Tuberculosis Study Status In Development Locality US & Non-US
P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants DAIDS Number 11882 Research Area Treatment Study Status Closed to Follow Up Locality Non-US
IMPAACT 2007: Phase I Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed Locality US & Non-US
P1006: Effects of HAART on Immune Function DAIDS Number 10036 Research Area Other Study Status Concluded Locality United States
IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age DAIDS Number 38530 Research Area Complications & Comorbidities Study Status Enrolling Locality United States